BACKGROUND: Multiple system atrophy (MSA) is a neurodegenerative disease leading to severe physical impairment, with a disease duration from onset to death of 6-9 years. METHODS: The clinical and neuropathological features of 4 MSA cases with disease duration of 15 years or more were analyzed. RESULTS: All patients presented with parkinsonism and had a mean latency of 11 years before the development of dysautonomia. Mean duration from onset of first symptoms to anterocollis, inspiratory stridor, and dysphagia was 9 years. Despite the limited levodopa response, all patients developed levodopa-induced dyskinesia. CONCLUSIONS: Late appearance of dysautonomia is a favorable prognostic factor in MSA-P. Greater awareness of this uncommon "benign" subgroup of MSA will improve diagnostic accuracy and help to more accurately inform treatment options.
BACKGROUND:Multiple system atrophy (MSA) is a neurodegenerative disease leading to severe physical impairment, with a disease duration from onset to death of 6-9 years. METHODS: The clinical and neuropathological features of 4 MSA cases with disease duration of 15 years or more were analyzed. RESULTS: All patients presented with parkinsonism and had a mean latency of 11 years before the development of dysautonomia. Mean duration from onset of first symptoms to anterocollis, inspiratory stridor, and dysphagia was 9 years. Despite the limited levodopa response, all patients developed levodopa-induced dyskinesia. CONCLUSIONS: Late appearance of dysautonomia is a favorable prognostic factor in MSA-P. Greater awareness of this uncommon "benign" subgroup of MSA will improve diagnostic accuracy and help to more accurately inform treatment options.
Authors: Iva Stankovic; Florian Krismer; Aleksandar Jesic; Angelo Antonini; Thomas Benke; Richard G Brown; David J Burn; Janice L Holton; Horacio Kaufmann; Vladimir S Kostic; Helen Ling; Wassilios G Meissner; Werner Poewe; Marija Semnic; Klaus Seppi; Atsushi Takeda; Daniel Weintraub; Gregor K Wenning Journal: Mov Disord Date: 2014-04-18 Impact factor: 10.338
Authors: Iva Stankovic; Niall Quinn; Luca Vignatelli; Angelo Antonini; Daniela Berg; Elizabeth Coon; Pietro Cortelli; Alessandra Fanciulli; Joaquim J Ferreira; Roy Freeman; Glenda Halliday; Günter U Höglinger; Valeria Iodice; Horacio Kaufmann; Thomas Klockgether; Vladimir Kostic; Florian Krismer; Anthony Lang; Johannes Levin; Phillip Low; Christopher Mathias; Wassillios G Meissner; Lucy Norcliffe Kaufmann; Jose-Alberto Palma; Jalesh N Panicker; Maria Teresa Pellecchia; Ryuji Sakakibara; Jeremy Schmahmann; Sonja W Scholz; Wolfgang Singer; Maria Stamelou; Eduardo Tolosa; Shoji Tsuji; Klaus Seppi; Werner Poewe; Gregor K Wenning Journal: Mov Disord Date: 2019-04-29 Impact factor: 10.338
Authors: Juan J Figueroa; Wolfgang Singer; Ajay Parsaik; Eduardo E Benarroch; J Eric Ahlskog; Robert D Fealey; Joseph E Parisi; Paola Sandroni; Jay Mandrekar; Valeria Iodice; Phillip A Low; James H Bower Journal: Mov Disord Date: 2014-06-07 Impact factor: 10.338
Authors: Eduardo De Pablo-Fernandez; Carmen Tur; Tamas Revesz; Andrew J Lees; Janice L Holton; Thomas T Warner Journal: JAMA Neurol Date: 2017-08-01 Impact factor: 18.302
Authors: Elizabeth A Coon; David M Sletten; Mariana D Suarez; Jay N Mandrekar; J Eric Ahlskog; James H Bower; Joseph Y Matsumoto; Michael H Silber; Eduardo E Benarroch; Robert D Fealey; Paola Sandroni; Phillip A Low; Wolfgang Singer Journal: Brain Date: 2015-09-13 Impact factor: 13.501
Authors: Alessandra Fanciulli; Stefano Strano; Jean Pierre Ndayisaba; Georg Goebel; Laura Gioffrè; Massimiliano Rizzo; Carlo Colosimo; Carlo Caltagirone; Werner Poewe; Gregor K Wenning; Francesco E Pontieri Journal: J Neurol Date: 2014-04-16 Impact factor: 4.849